Baruch Halpert
Vorsitzender bei Terragenic International Ltd.
Profil
Baruch Halpert is currently the Executive Chairman at Terragenic International Ltd.
He previously worked as a Director at Enlivex Therapeutics Ltd.
and holds a graduate degree from The University of Reading.
Aktive Positionen von Baruch Halpert
Unternehmen | Position | Beginn |
---|---|---|
Terragenic International Ltd. | Vorsitzender | 01.01.2018 |
Ehemalige bekannte Positionen von Baruch Halpert
Unternehmen | Position | Ende |
---|---|---|
ENLIVEX THERAPEUTICS LTD. | Direktor/Vorstandsmitglied | - |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Direktor/Vorstandsmitglied | - |
Ausbildung von Baruch Halpert
The University of Reading | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Private Unternehmen | 2 |
---|---|
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Terragenic International Ltd. |